BPG is committed to discovery and dissemination of knowledge
Home / Archive / Volume 17, Issue 3
  • This Article
Peer-Review Report of This Article
CrossCheck and Google Search of This Article
Academic Rules and Norms of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Journal Information of This Article
Publication Name
World Journal of Gastrointestinal Pharmacology and Therapeutics
ISSN
2150-5349
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Minireviews
Copyright: ©Author(s) 2026. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license. No commercial re-use. See permissions. Published by Baishideng Publishing Group Inc.
World J Gastrointest Pharmacol Ther. Sep 5, 2026; 17(3): 120122
Published online Sep 5, 2026. doi: 10.4292/wjgpt.120122
Nor-ursodeoxycholic acid in hepatobiliary diseases: A narrative review
Sayan Malakar, Neha Sood, Suprabhat Giri, Arghya Samanta
Sayan Malakar, Department of Hepatology and Liver Transplantation, Punjab Institute of Liver and Biliary Sciences, Mohali 160059, Punjab, India
Neha Sood, Department of Internal Medicine, Post Graduate Institution of Medical Education and Research, Chandigarh 160012, India
Suprabhat Giri, Department of Gastroenterology and Hepatology, Kalinga Institute of Medical Sciences, Bhubaneswar 751024, Odisha, India
Arghya Samanta, Department of Pediatric Gastroenterology, Institute of Post Graduate Medical Education and Research, Kolkata 700020, West Bengal, India
Author contributions: Malakar S has conceptualised and designed the manuscript; Malakar S and Sood N drafted the initial manuscript; Malakar S, Sood N, Giri S, and Samanta A contributed to the literature review, analysis, data collection, interpretation, critical revision of the initial manuscript, and approved the final version of the manuscript.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
Corresponding author: Sayan Malakar, Assistant Professor, Department of Hepatology and Liver Transplantation, Punjab Institute of Liver and Biliary Sciences, 1210 Sector 77, Mohali 160059, Punjab, India. oneandonlydrsayan@gmail.com
Received: February 24, 2026
Revised: April 9, 2026
Accepted: May 29, 2026
Published online: September 5, 2026
Processing time: 193 Days and 15.7 Hours
Core Tip

Core Tip: Nor-ursodeoxycholic acid or norucholic acid is a short-chain shortened derivative of ursodeoxycholic acid. Pre-clinical animal studies have revealed conflicting results. Clinical data on primary cholestatic liver diseases and metabolic dysfunction-associated liver diseases are also limited. This narrative review comprehensively explores the mechanism of action and discusses the pharmacokinetics and pharmacodynamic differences with ursodeoxycholic acid. It also addresses the potential gap in the literature regarding the role of nor-ursodeoxycholic acid in metabolic dysfunction-associated liver diseases and primary sclerosing cholangitis based on primitive data.
Write to the Help Desk
Copyright © 1993-2026 Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA. All rights reserved, including rights relating to text and data mining, AI training, and similar technologies. For open-access content, the applicable copyright and licensing terms govern.